Legal & General Group Plc Purchases Shares of 54,930 Alumis Inc. $ALMS

Legal & General Group Plc acquired a new position in Alumis Inc. (NASDAQ:ALMS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 54,930 shares of the company’s stock, valued at approximately $1,546,000.

Several other hedge funds have also modified their holdings of ALMS. BlackRock Inc. purchased a new position in shares of Alumis in the second quarter valued at $231,259,000. MPM Bioimpact LLC purchased a new stake in Alumis during the fourth quarter valued at $23,443,000. Janus Henderson Group PLC bought a new position in Alumis during the first quarter valued at $46,790,000. Orbimed Advisors LLC bought a new position in Alumis during the second quarter valued at $5,779,000. Finally, Woodline Partners LP grew its stake in shares of Alumis by 809.7% in the 3rd quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock worth $6,987,000 after buying an additional 1,558,660 shares in the last quarter.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Citigroup restated an “overweight” rating on shares of Alumis in a research report on Tuesday, September 1st. Guggenheim cut Alumis from a “buy” rating to a “neutral” rating in a research note on Thursday. Oppenheimer decreased their price objective on Alumis from $55.00 to $37.00 and set an “outperform” rating on the stock in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a research note on Tuesday, July 7th. Finally, Robert W. Baird set a $27.00 target price on Alumis in a report on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $33.27.

Insider Activity

In other Alumis news, insider Jorn Drappa sold 2,447 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $64,527.39. Following the sale, the insider owned 56,892 shares in the company, valued at $1,500,242.04. This trade represents a 4.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mark Bradley sold 2,572 shares of Alumis stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $67,823.64. Following the sale, the insider owned 48,533 shares of the company’s stock, valued at approximately $1,279,815.21. This trade represents a 5.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 19,953 shares of company stock worth $534,311 in the last three months. Corporate insiders own 33.70% of the company’s stock.

Trending Headlines about Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: HC Wainwright upgraded its rating on Alumis. The upgrade helped support an earlier rebound in the shares, although its effect was subsequently overshadowed by the lupus-trial news. Alumis Stock Rating Upgraded by HC Wainwright
• Positive Sentiment: Alumis will participate in several September investor conferences. These events could give management an opportunity to explain the clinical results, discuss its broader pipeline and outline its strategy for using biomarker data to identify potentially responsive lupus patients. Alumis to Participate in Upcoming September Investor Conferences
• Neutral Sentiment: Options activity was unusually high. Elevated options trading indicates increased investor positioning and volatility following the clinical announcement, but it does not establish a clear directional outlook. Alumis Target of Unusually Large Options Trading
• Negative Sentiment: Alumis’ Phase 2b lupus study missed its key endpoints. The mixed data for the company’s lead SLE treatment raised concerns about the drug’s efficacy and commercial prospects, triggering a sharp decline in the stock. Management’s potential biomarker-based development strategy may preserve a path forward, but it also adds uncertainty and could require additional clinical work. Alumis Lead Lupus Drug Missed Phase 2b Trial Endpoints
• Negative Sentiment: Guggenheim downgraded Alumis from Buy to Neutral after the trial setback. The downgrade reflects reduced confidence in the lupus program and likely contributed to continued selling pressure. Additional analyst commentary has focused on the implications of the clinical miss for valuation and the company’s pipeline. Alumis Downgraded at Guggenheim

Alumis Price Performance

Alumis stock opened at $11.10 on Monday. Alumis Inc. has a 1-year low of $3.76 and a 1-year high of $31.35. The firm has a market capitalization of $1.44 billion, a P/E ratio of -2.88 and a beta of -0.81. The company’s 50-day moving average is $25.33 and its 200 day moving average is $24.60.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.34). The firm had revenue of $1.66 million during the quarter, compared to the consensus estimate of $3.65 million. Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%. Research analysts anticipate that Alumis Inc. will post -2.95 earnings per share for the current fiscal year.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.